SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
JULY 26, 2000
----------------
(Date of Report)
ENTROPIN, INC.
-----------------------------------------------------
(Exact Name of Registrant as specified in its charter)
COLORADO 33-23693 84-1090424
---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
45926 OASIS STREET, INDIO, CALIFORNIA 92201
------------------------------------------------------------
(Address of principal executive offices including zip code)
(760) 775-8333
----------------------------------------------------
(Registrant's telephone number including area code)
N/A
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
---------------------
Entropin, Inc. ("Entropin") has executed a letter of intent to engage
Glenmere Clinical Research, Inc. ("GCR") to provide the continuing depth
of assistance and expertise required for the remaining clinical and regulatory
processes of preparing, submitting, filing and finalizing approval of a
New Drug Application for Esterom(R). GCR will continue as a replacement for
Western Center for Clinical Studies, Inc. ("WCCS"), who completed the
enrollment process for the phase IIIA clinical trials. Upon completion of
such enrollment, Entropin and WCCS negotiated the termination of their
clinical and regulatory consulting agreements as of July 10, 2000.
SIGNATURES
----------
-3-
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: July 26, 2000 ENTROPIN, INC.
By /s/ Thomas G. Tachovsky
------------------------------------
Thomas G. Tachovsky
President and Chief Executive Officer
-2-
